{"id":"https://genegraph.clinicalgenome.org/r/84ea1b39-acad-4a24-8122-530a53225345v1.0","type":"EvidenceStrengthAssertion","dc:description":"The relationship between the PSAP gene and atypical Gaucher disease due to saposin C deficiency (GDSAPC), an autosomal recessive lysosomal storage disorder, was evaluated using the ClinGen Clinical Validity Framework as of September 6, 2022. PSAP encodes prosaposin (pSap), a precursor protein that is cleaved in the endosome to form saposins A-D, which are small glycoproteins involved in sphingolipid degradation via activating lysosomal hydrolases; saposin C activates glucocerebrosidase for the hydrolysis of glucosylceramide in lysosomes (as reviewed in PMID: 22652185). Among patients with GDSAPC, deficiency of saposin C results in impaired glucocerebrosidase activation, causing lysosomal accumulation of glucocerebroside (PMID: 20484222), which leads in the characteristic clinical manifestations of Gaucher’s disease which include hepatosplenomegaly, thrombocytopenia, bone lesions, anemia, and in some cases, neurologic anomalies (as reviewed in PMID: 15464415)\n\nThe disease mechanism of GDSAPC is loss of function. GDSAPC was first reported by Christomanou et al. in 1986 (PMID: 3024666) and the first report of biallelic variants in PSAP among GDSAPC cases was by Diaz-Font in 2005 (PMID: 15856305). Both case-level (genetic) and experimental evidence support the relationship between PSAP and GDSAPC. Reported causal variants include missense, nonsense, deletions, and splice-altering variants (PMID: 20484222, PMID: 15856305, PMID: 2060627, PMID: 17919309, PMID: 28457694, PMID: 35316504, PMID: 31061751, PMID: 35456468). In total, thirteen variants from nine probands in eight publications were curated. Although there is additional published case-level evidence available, the maximum score for genetic evidence (12 points) has already been reached. \n\nExperimental evidence for the relationship between PSAP and GDSAPC includes: the biochemical function of the gene product (prosaposin) being consistent with the clinical and biochemical findings identified individuals with GDSAPC (PMID: 20484222, PMID: 22652185, PMID: 15464415); the biochemical and clinical features of PSAP knockout mice (PMID: 20015957); and partial rescue of central nervous system glucocerebrosidase accumulation and neurologic impairment via insertion of saposin C cDNA into PSAP knockout mice (PMID: 12208132). Additional experimental evidence is available, but the maximum score for experimental evidence (6 points) has already been reached.\n\nIn sum, PSAP is definitively associated with GDSAPC. The association has been repeatedly demonstrated in both clinical and research settings, and has been upheld over time. Classification aproved by the Clingen Lysosomal Diseases Gene Curation Expert Panel on October 6, 2022 (SOP v9).","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/84ea1b39-acad-4a24-8122-530a53225345","GCISnapshot":"https://genegraph.clinicalgenome.org/r/e949cb92-7d76-471e-9e37-44fd7f00964b","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/e949cb92-7d76-471e-9e37-44fd7f00964b_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10110","date":"2023-06-26T16:09:24.802Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/e949cb92-7d76-471e-9e37-44fd7f00964b_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10110","date":"2023-06-26T16:00:00.000Z","role":"Approver"}],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e949cb92-7d76-471e-9e37-44fd7f00964b_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e949cb92-7d76-471e-9e37-44fd7f00964b_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2779e196-80d0-4577-b25e-bbf587b44cc8","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7f057131-7f7f-4569-9e66-e70e124dcbf0","type":"Finding","dc:description":"Saposin C knockout mice show absent saposin C protein and normal levels of saposins A, B, and D, cellular accumulation of glucocerebroside, and neurologic impairment including hind limb weakness, impaired hippocampal long-term potentiation, and progressive ataxia, recapitulating key features of the human disease phenotype","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20015957","rdfs:label":"Saposin C knockout mouse","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/ca4e0ef2-41bd-4720-89f0-cd1703f48a6c","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3921fe34-12eb-444f-8d39-4869a12f8761","type":"Finding","dc:description":"PS-N-A mice show increased life span and delayed onset of neurologic symptoms with lessened severity versus PS-/- (PSAP knockout) mice and partial correction of accumulation of glucocerebrosidase in the brain","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12208132","rdfs:label":"Rescue of PS-/- mice via PSAP transgene","demonstrates":{"id":"cg:PhenotypeRescue"}}],"specifiedBy":"GeneValidityNonHumanRescueCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":4},{"id":"https://genegraph.clinicalgenome.org/r/e949cb92-7d76-471e-9e37-44fd7f00964b_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6540fb4d-c3d9-40a7-9c89-2669d6136b80","type":"EvidenceLine","dc:description":"Per ClinGen LD GCEP guidelines, gene products that have a well-established function in a metabolic pathway are scored 2 points","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3e260788-63e7-4d08-88f2-bc66afe08184","type":"Finding","dc:description":"PSAP encodes prosaposin (pSap), a precursor protein that is cleaved in the endosome to form saposins A-D, which are small glycoproteins involved in sphingolipid degradation via activating lysosomal hydrolases; saposin C activates glucocerebrosidase for the hydrolysis of glucosylceramide in lysosomes (as reviewed in PMID: 22652185). Among patients with atypical Gaucher disease due to saposin C, deficiency of saposin C results in impaired glucocerebrosidase activation, leading to lysosomal accumulation of glucocerebroside (PMID: 20484222), which results in the characteristic clinical manifestations of Gaucher’s disease which include hepatosplenomegaly, thrombocytopenia, bone lesions, anemia, and in some cases, neurologic anomalies (as reviewed in PMID: 15464415). ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20484222","rdfs:label":"Saposin C deficiency impairs glucosylcerebroside breakdown","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":6},{"id":"https://genegraph.clinicalgenome.org/r/e949cb92-7d76-471e-9e37-44fd7f00964b_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cf44f2a4-7ae6-4135-a2b8-15bb38a0ff15_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/97193a57-429a-4d89-815e-cc9c14848936","type":"EvidenceLine","dc:description":"Scored 0.75pts per variant to yield 1.5pts total and prevent double-counting for homozygous variant","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/97193a57-429a-4d89-815e-cc9c14848936_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31061751","allele":{"id":"https://genegraph.clinicalgenome.org/r/7eea781e-3a0e-4cec-a55d-d72a0e8b9367","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002778.4(PSAP):c.1228G>T (p.Glu410Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA377143714"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/cf44f2a4-7ae6-4135-a2b8-15bb38a0ff15","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31061751","rdfs:label":"Patient 1-Rama Devi","allele":{"id":"https://genegraph.clinicalgenome.org/r/7eea781e-3a0e-4cec-a55d-d72a0e8b9367"},"firstTestingMethod":"Exome sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/97193a57-429a-4d89-815e-cc9c14848936_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/e949cb92-7d76-471e-9e37-44fd7f00964b_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0f1acb1e-56cc-4274-bbae-1bd0caeb64b6_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35456468","rdfs:label":"DEM4599","estimatedLodScore":2.43,"family":{"id":"https://genegraph.clinicalgenome.org/r/0f1acb1e-56cc-4274-bbae-1bd0caeb64b6","type":"Family","rdfs:label":"DEM4599","member":{"id":"https://genegraph.clinicalgenome.org/r/9fd0f637-d93d-452d-83dc-32ade7e4fb89","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35456468","rdfs:label":"IV-5","allele":{"id":"https://genegraph.clinicalgenome.org/r/2ba4ccd9-06aa-46e0-ad52-cd99ce153b6f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002778.4(PSAP):c.1076A>C (p.Glu359Ala)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/991967"}},"firstTestingMethod":"Exome sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/7ca3a5a7-7b9a-47ec-a5aa-58266b6a6ae7_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35456468","allele":{"id":"https://genegraph.clinicalgenome.org/r/2ba4ccd9-06aa-46e0-ad52-cd99ce153b6f"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}}},"meetsInclusionCriteria":true,"phenotypeNegativeAlleleNegative":5,"phenotypePositiveAllelePositive":4,"proband":{"id":"https://genegraph.clinicalgenome.org/r/9fd0f637-d93d-452d-83dc-32ade7e4fb89"},"publishedLodScore":3.98,"sequencingMethod":{"id":"cg:AllGenesSequencing"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/47115ba5-d04b-443c-b350-abacb3764a99_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4e34c348-3cde-46dc-aa91-10e22b6fc9c2","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4e34c348-3cde-46dc-aa91-10e22b6fc9c2_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15856305","allele":{"id":"https://genegraph.clinicalgenome.org/r/fcd7f4bb-2ce8-4059-b479-990136ba22fa","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002778.4(PSAP):c.1288C>T (p.Gln430Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA123067"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/4a63f624-494c-4e0d-80c8-9c18217a20ba","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4a63f624-494c-4e0d-80c8-9c18217a20ba_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Functional evidence - PMID: 24925315: when overexpressed in COS-1 cells, half-life (as assessed by treatment with the protein synthesis inhibitor cycloheximide (CHX)), showed significantly reduced half-life and increased instability versus wild-type Sap C protein ","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/4a63f624-494c-4e0d-80c8-9c18217a20ba_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15856305","allele":{"id":"https://genegraph.clinicalgenome.org/r/73fe3d9d-e6c2-46b3-9bce-2968ee47e8d3","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002778.4(PSAP):c.1144T>G (p.Cys382Gly)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA123065"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/47115ba5-d04b-443c-b350-abacb3764a99","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15856305","rdfs:label":"Patient 1 - Diaz-Font","allele":[{"id":"https://genegraph.clinicalgenome.org/r/fcd7f4bb-2ce8-4059-b479-990136ba22fa"},{"id":"https://genegraph.clinicalgenome.org/r/73fe3d9d-e6c2-46b3-9bce-2968ee47e8d3"}],"firstTestingMethod":"PCR","previousTesting":false,"secondTestingMethod":"Sanger sequencing","sex":"Male","variant":[{"id":"https://genegraph.clinicalgenome.org/r/4e34c348-3cde-46dc-aa91-10e22b6fc9c2_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/4a63f624-494c-4e0d-80c8-9c18217a20ba_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2.0},{"id":"https://genegraph.clinicalgenome.org/r/e48781a3-47c7-443d-aea2-325d420b65f1_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f33558b5-5993-405c-9be9-53ae59289b0c","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f33558b5-5993-405c-9be9-53ae59289b0c_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17919309","allele":{"id":"https://genegraph.clinicalgenome.org/r/0512f062-8d0c-49f0-bb11-9d7b240b957b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002778.4(PSAP):c.1A>T (p.Met1Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA123061"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/dda8f110-405f-4fb7-a46e-cdf0f3046fed","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/dda8f110-405f-4fb7-a46e-cdf0f3046fed_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"PMID: 24925315: when overexpressed in COS-1 cells, half-life (as assessed by treatment with the protein synthesis inhibitor cycloheximide (CHX)), showed significantly reduced half-life and increased instability versus wild-type Sap C protein ","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/dda8f110-405f-4fb7-a46e-cdf0f3046fed_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17919309","allele":{"id":"https://genegraph.clinicalgenome.org/r/9d598cd1-6ad6-4733-a9b1-2afd4e9c4b66","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002778.4(PSAP):c.1046T>C (p.Leu349Pro)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA123069"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/e48781a3-47c7-443d-aea2-325d420b65f1","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17919309","rdfs:label":"MZ","allele":[{"id":"https://genegraph.clinicalgenome.org/r/9d598cd1-6ad6-4733-a9b1-2afd4e9c4b66"},{"id":"https://genegraph.clinicalgenome.org/r/0512f062-8d0c-49f0-bb11-9d7b240b957b"}],"firstTestingMethod":"PCR","sex":"Male","variant":[{"id":"https://genegraph.clinicalgenome.org/r/dda8f110-405f-4fb7-a46e-cdf0f3046fed_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/f33558b5-5993-405c-9be9-53ae59289b0c_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2.0},{"id":"https://genegraph.clinicalgenome.org/r/5fd99b07-5cec-4233-ae2e-729a306170e6_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/906db80d-1ded-4de9-90a7-7ec8e85c2ed6","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/906db80d-1ded-4de9-90a7-7ec8e85c2ed6_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Functional evidence - PMID: 24925315: when overexpressed in COS-1 cells, half-life (as assessed by treatment with the protein synthesis inhibitor cycloheximide (CHX)), showed significantly reduced half-life and increased instability versus wild-type Sap C protein ","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/906db80d-1ded-4de9-90a7-7ec8e85c2ed6_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/2060627","allele":{"id":"https://genegraph.clinicalgenome.org/r/8ce42bec-8fd8-45f1-974b-2d889a2f908d","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002778.4(PSAP):c.1145G>T (p.Cys382Phe)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA123059"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/5fd99b07-5cec-4233-ae2e-729a306170e6","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/2060627","rdfs:label":"Patient 1 - Schnabel","allele":{"id":"https://genegraph.clinicalgenome.org/r/8ce42bec-8fd8-45f1-974b-2d889a2f908d"},"detectionMethod":"Only a single (heterozygous) variant detected; second allele not identified","firstTestingMethod":"PCR","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/906db80d-1ded-4de9-90a7-7ec8e85c2ed6_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/eef04bd8-4064-45de-9f1b-6457a5529409_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4d81beec-1423-4b97-b320-8d9a87121dec","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4d81beec-1423-4b97-b320-8d9a87121dec_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20484222","allele":{"id":"https://genegraph.clinicalgenome.org/r/28bf82a0-5dd3-4bff-a4a0-210e65239f3f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002778.4(PSAP):c.1A>G (p.Met1Val)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA5547949"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/bfb2101c-fdbf-4e1f-aeea-2e3501d291fc","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bfb2101c-fdbf-4e1f-aeea-2e3501d291fc_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"PMID: 24925315: when overexpressed in COS-1 cells, half-life (as assessed by treatment with the protein synthesis inhibitor cycloheximide (CHX)), showed significantly reduced half-life and increased instability versus wild-type Sap C protein","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/bfb2101c-fdbf-4e1f-aeea-2e3501d291fc_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20484222","allele":{"id":"https://genegraph.clinicalgenome.org/r/7917621e-b497-4dd8-b865-e39ebb32ff89","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002778.4(PSAP):c.943T>A (p.Cys315Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA377146091"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/eef04bd8-4064-45de-9f1b-6457a5529409","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20484222","rdfs:label":"Patient 3","allele":[{"id":"https://genegraph.clinicalgenome.org/r/7917621e-b497-4dd8-b865-e39ebb32ff89"},{"id":"https://genegraph.clinicalgenome.org/r/28bf82a0-5dd3-4bff-a4a0-210e65239f3f"}],"sex":"Female","variant":[{"id":"https://genegraph.clinicalgenome.org/r/bfb2101c-fdbf-4e1f-aeea-2e3501d291fc_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/4d81beec-1423-4b97-b320-8d9a87121dec_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2.0},{"id":"https://genegraph.clinicalgenome.org/r/1f9ee441-25d1-4b2c-acfd-86d0190e0783_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f7488f9b-0dbb-4c98-a2e6-8b2699cdfd10","type":"EvidenceLine","dc:description":"Scored 0.75pts per variant to yield 1.5pts total and prevent double-counting for homozygous variant","calculatedScore":3.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f7488f9b-0dbb-4c98-a2e6-8b2699cdfd10_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35316504","allele":{"id":"https://genegraph.clinicalgenome.org/r/a9d39f05-b280-42f9-ad73-f92a6fa4db93","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002778.4(PSAP):c.1005+1G>A","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/1330309"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/1f9ee441-25d1-4b2c-acfd-86d0190e0783","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/35316504","rdfs:label":"Patient 1-Mohamed","allele":{"id":"https://genegraph.clinicalgenome.org/r/a9d39f05-b280-42f9-ad73-f92a6fa4db93"},"detectionMethod":"PCR and Sanger sequencing of PSAP; GBA gene also tested using the same method ","firstTestingMethod":"PCR","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/f7488f9b-0dbb-4c98-a2e6-8b2699cdfd10_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/21de1b09-0c9b-4702-98c6-1e6cee319760_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e866cfd4-d4ea-483e-9916-e3a6b33522bd","type":"EvidenceLine","dc:description":"Scored 1.5pts to account for the second variant, the exon 2-7 deletion (chr10:g.73583712_73594178del; CACN643459681), which is a predicted null variant. The deletion variant could not be entered independently in the ClinGen Gene Curation Interface (GCI), as currently the GCI does not accept variants that are >1000bp in length and have only CACNAIDs, as is the case for this variant. ","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e866cfd4-d4ea-483e-9916-e3a6b33522bd_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28457694","allele":{"id":"https://genegraph.clinicalgenome.org/r/35252cda-a2ff-45d6-b0fa-29d331bbadfb","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002778.4(PSAP):c.1133C>G (p.Pro378Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA377144171"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/21de1b09-0c9b-4702-98c6-1e6cee319760","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28457694","rdfs:label":"Patient 1 - Kang","allele":{"id":"https://genegraph.clinicalgenome.org/r/35252cda-a2ff-45d6-b0fa-29d331bbadfb"},"detectionMethod":"PCR and Sanger sequencing identified the c.1133C>G (p.Pro378Arg) variant; whole genome sequencing identified the exon 2-7 deletion ","firstTestingMethod":"Sanger sequencing","secondTestingMethod":"Whole genome shotgun sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/e866cfd4-d4ea-483e-9916-e3a6b33522bd_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/9fd0f637-d93d-452d-83dc-32ade7e4fb89_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7ca3a5a7-7b9a-47ec-a5aa-58266b6a6ae7","type":"EvidenceLine","calculatedScore":0.2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7ca3a5a7-7b9a-47ec-a5aa-58266b6a6ae7_variant_evidence_item"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/9fd0f637-d93d-452d-83dc-32ade7e4fb89"}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.2},{"id":"https://genegraph.clinicalgenome.org/r/58ea49b6-2400-4386-a38e-aea6a46bf10f_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b36d1b50-57a1-4cc0-a423-240302c82318","type":"EvidenceLine","dc:description":"Scored 0.25pts per variant to prevent double-counting for homozygous variant","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b36d1b50-57a1-4cc0-a423-240302c82318_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"PMID: 24925315: in transfected COS-7 cells, resulted in significantly reduced expression versus wild-type protein; when overexpressed in COS-1 cells, half-life (as assessed by treatment with the protein synthesis inhibitor cycloheximide (CHX)), showed significantly reduced half-life and increased instability versus wild-type Sap C protein","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/b36d1b50-57a1-4cc0-a423-240302c82318_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20484222","allele":{"id":"https://genegraph.clinicalgenome.org/r/197d366a-e8e7-4864-b3db-f93639048f9f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002778.4(PSAP):c.1024_1044del (p.Phe342_Lys348del)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2573320569"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/58ea49b6-2400-4386-a38e-aea6a46bf10f","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20484222","rdfs:label":"Patient 4","allele":{"id":"https://genegraph.clinicalgenome.org/r/197d366a-e8e7-4864-b3db-f93639048f9f"},"sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/b36d1b50-57a1-4cc0-a423-240302c82318_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12}],"evidenceStrength":"Definitive","sequence":6517,"specifiedBy":"GeneValidityCriteria9","strengthScore":18,"subject":{"id":"https://genegraph.clinicalgenome.org/r/1bJ3r_3KTBs","type":"GeneValidityProposition","disease":"obo:MONDO_0012517","gene":"hgnc:9498","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_e949cb92-7d76-471e-9e37-44fd7f00964b-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}